Overview A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients Status: Not yet recruiting Trial end date: 2026-12-31 Target enrollment: Participant gender: Summary A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate the Efficacy and Safety of HGP2102 in patients with Essential Hypertension Phase: Phase 3 Details Lead Sponsor: Hanmi Pharmaceutical Company Limited